Skip to content

Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery

Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During Cardiac Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02757118
Enrollment
30
Registered
2016-04-29
Start date
2016-05-31
Completion date
2017-01-31
Last updated
2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery

Keywords

Cardiac Surgery, blood viscosity

Brief summary

After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing cardiac surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15). All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). After printing the envelope number outside envelope, all sealed envelopes with cards will be conveyed to and kept in pharmacy department. According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture. Patient data and statistical analyses: Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge. All statistical analyses will be performed after the 30th patient's discharge and data acquisition

Interventions

crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

Sponsors

Konkuk University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing coiling embolization procedure due to cardiac surgery * Patients provided a written informed consent. * Patients with preoperative serum hemoglobin concentration \>13 g/dL (male) and \>12 g/dL (female) * Patients with PaO2/FiO2 ratio \>150

Exclusion criteria

* Patients with history of anemia, dyspnea, active infection. * Patients with endocrine disease * Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-platelet drug, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing cardiac surgery.

Design outcomes

Primary

MeasureTime frame
whole blood viscositywith 1 hour after the completion of procedure

Secondary

MeasureTime frameDescription
PaO2/FiO2 ratiowith 1 hour after the completion of procedurePaO2/FiO2 ratio measured by arterial blood gas analysis
hematocritwith 1 hour after the completion of procedureserum hematocrit, %
glucosewith 1 hour after the completion of procedureserum glucose level, g/dl
osmolaritywith 1 hour after the completion of procedureserum osmolarity, mOsm
urine outputwith 1 hour after the completion of procedurehourly urine output, ml/hr
Maximum clot formationwith 1 hour after the completion of procedureMaximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm

Contacts

Primary ContactTae-Yop Kim, MD, PhD
taeyop@gmail.com82-2-2030-5448

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026